Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioXcel Therapeutics (BTAI) Interest Expenses (2022 - 2025)

Historic Interest Expenses for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $4.4 million.

  • BioXcel Therapeutics' Interest Expenses rose 1538.26% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year increase of 1436.83%. This contributed to the annual value of $15.1 million for FY2024, which is 1363.23% up from last year.
  • Latest data reveals that BioXcel Therapeutics reported Interest Expenses of $4.4 million as of Q3 2025, which was up 1538.26% from $4.2 million recorded in Q2 2025.
  • BioXcel Therapeutics' Interest Expenses' 5-year high stood at $4.4 million during Q3 2025, with a 5-year trough of $7000.0 in Q1 2022.
  • Over the past 4 years, BioXcel Therapeutics' median Interest Expenses value was $3.6 million (recorded in 2024), while the average stood at $3.3 million.
  • Within the past 5 years, the most significant YoY rise in BioXcel Therapeutics' Interest Expenses was 4800000.0% (2023), while the steepest drop was 1210.81% (2023).
  • BioXcel Therapeutics' Interest Expenses (Quarter) stood at $2.9 million in 2022, then grew by 17.64% to $3.4 million in 2023, then grew by 17.38% to $4.0 million in 2024, then increased by 8.46% to $4.4 million in 2025.
  • Its Interest Expenses stands at $4.4 million for Q3 2025, versus $4.2 million for Q2 2025 and $4.0 million for Q1 2025.